A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

NCT02087917 ↗

Phase 2 Completed 376 enrolled Zhejiang Hisun Pharmaceutical Co. Ltd. Covance · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with primary hypercholesterolemia.

Timeline

Start: 2014-03
Primary completion: 2014-09
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	HYZETIMIBE	Small molecule	5 mg	Oral
Comparator	HYZETIMIBE	Small molecule	10 mg	Oral
Comparator	HYZETIMIBE	Small molecule	20 mg	Oral
Comparator	HYZETIMIBE	Small molecule	30 mg	Oral

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Summary

Timeline

Drugs

Indications